Compare Aurobindo Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs SUN PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA SUN PHARMA AUROBINDO PHARMA/
SUN PHARMA
 
P/E (TTM) x 16.3 24.6 66.3% View Chart
P/BV x 3.0 2.6 114.7% View Chart
Dividend Yield % 0.4 0.6 57.4%  

Financials

 AUROBINDO PHARMA   SUN PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
SUN PHARMA
Mar-19
AUROBINDO PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs830679 122.3%   
Low Rs527375 140.4%   
Sales per share (Unadj.) Rs333.9121.1 275.6%  
Earnings per share (Unadj.) Rs40.413.4 301.7%  
Cash flow per share (Unadj.) Rs51.820.7 250.2%  
Dividends per share (Unadj.) Rs2.502.75 90.9%  
Dividend yield (eoy) %0.40.5 70.6%  
Book value per share (Unadj.) Rs237.1172.6 137.4%  
Shares outstanding (eoy) m585.912,399.26 24.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.04.4 46.7%   
Avg P/E ratio x16.839.4 42.7%  
P/CF ratio (eoy) x13.125.5 51.4%  
Price / Book Value ratio x2.93.1 93.7%  
Dividend payout %6.220.6 30.1%   
Avg Mkt Cap Rs m397,5691,264,650 31.4%   
No. of employees `00017.917.5 102.0%   
Total wages/salary Rs m25,84959,671 43.3%   
Avg. sales/employee Rs Th10,956.916,608.1 66.0%   
Avg. wages/employee Rs Th1,447.73,409.6 42.5%   
Avg. net profit/employee Rs Th1,324.31,833.8 72.2%   
INCOME DATA
Net Sales Rs m195,636290,659 67.3%  
Other income Rs m1,55310,255 15.1%   
Total revenues Rs m197,189300,914 65.5%   
Gross profit Rs m39,51963,076 62.7%  
Depreciation Rs m6,68017,533 38.1%   
Interest Rs m2,6265,553 47.3%   
Profit before tax Rs m31,76750,246 63.2%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881-12,144 7.3%   
Tax Rs m7,2696,009 121.0%   
Profit after tax Rs m23,64532,093 73.7%  
Gross profit margin %20.221.7 93.1%  
Effective tax rate %22.912.0 191.3%   
Net profit margin %12.111.0 109.5%  
BALANCE SHEET DATA
Current assets Rs m153,645310,692 49.5%   
Current liabilities Rs m120,429173,396 69.5%   
Net working cap to sales %17.047.2 35.9%  
Current ratio x1.31.8 71.2%  
Inventory Days Days13599 136.5%  
Debtors Days Days64112 57.1%  
Net fixed assets Rs m103,909232,477 44.7%   
Share capital Rs m5862,399 24.4%   
"Free" reserves Rs m138,322411,691 33.6%   
Net worth Rs m138,908414,091 33.5%   
Long term debt Rs m1,80015,226 11.8%   
Total assets Rs m264,544646,938 40.9%  
Interest coverage x13.110.0 130.3%   
Debt to equity ratio x00 35.2%  
Sales to assets ratio x0.70.4 164.6%   
Return on assets %9.95.8 170.7%  
Return on equity %17.07.8 219.6%  
Return on capital %23.810.2 234.4%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31666,025 147.4%   
Fx outflow Rs m40,58938,610 105.1%   
Net fx Rs m56,72727,415 206.9%   
CASH FLOW
From Operations Rs m16,22021,965 73.8%  
From Investments Rs m-28,768-6,813 422.3%  
From Financial Activity Rs m19,191-27,305 -70.3%  
Net Cashflow Rs m6,656-8,442 -78.9%  

Share Holding

Indian Promoters % 54.1 63.7 84.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 5.1 155.0%  
FIIs % 27.7 23.0 120.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 8.3 122.9%  
Shareholders   69,601 133,026 52.3%  
Pledged promoter(s) holding % 8.6 0.5 1,615.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 995 Points Higher; Banking and IT Stocks Witness Huge Buying(Closing)

Indian share markets continued their momentum during closing hours today and ended on a strong note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Protect Your Wealth from Fund Managers(Fast Profits Daily)

May 14, 2020

Do you know how much you are paying in fees to your mutual fund? In this video I'll share with you my views.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

Why Buffet - and you - should study Quantum Liquid Fund(The Honest Truth)

May 14, 2020

Ajit Dayal on how Quantum Liquid Fund and Warren Buffett have similar investing styles.

More

Get Rich as the
Market Rebounds from Covid-19

Coronavirus Rebound
Get this special guide, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


May 27, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS